Introduction: The treatment of benign prostate hyperplasia (BPH) presents 2 options: medical or surgical, and there are doubts about what is the best treatment since 80% of patients who undergo surgery become asymptomatic and 10 to 40% of those under medical regimen undergo surgery within a 5 years period. It is difficult to assess the actual costs of treating BPH in Brazil due to several factors, among them regional particularities and the scarcity of current statistical data.
INTRODUCTION
Benign prostate hyperplasia (BPH) is very frequent in men and its prevalence increases with age, reaching figures of 85% to 90% in the age range above 80 years (1) . The intensity lower urinary tract symptoms fluctuates with time and may no be consequent to BPH (2) . This fact makes the identification of defined criteria difficult for indicating treatment, since about 80% of patients subjected to surgery become asymptomatic (3) . Brazilian consensus tried to define some parameters for guidance when indicating any type of treatment for BPH based in IPSS score. Thus, observation was recommended for cases with scores lower than 8. For patients with values between 8 and 19 pharmacological treatment would be indicated, and above these levels (20 to 35) the option would be surgical (4) . In the United States of America, transurethral resection of the prostate (TURP) is the second most performed surgical procedure, with an estimated cost between 2 to 3 billion dollars per year. As for costs with pharmacological treatment during a 5-year period, it is expected to range between US$ 1,800.00 and US$ 3,150.00 dollars/patient (5) . The purpose of the present work was to estimate, with data from the Brazilian population, which would be the cost of BPH treatment.
MATERIALS AND METHODS
In 1997 it was made a screening for early diagnosis of prostate cancer, where 1,106 volunteers were examined. The IPSS and quality of life were verified in all patients. To assess the participation of patients only with BPH, patients presenting cancer, intraepithelial neoplasia or those who refused biopsies when indicated were excluded, with 934 volunteers remaining for study. The results from this assessment allowed the creation of a table referent to frequency and distribution of lower urinary tract symptoms and signs in age ranges between 40 years and 79 years (Table-1), as well as score classification according to what was determined by the National consensus on BPH (6) ( Table-2 ). The number of men pertaining to each age range existing in Brazil was obtained from the national census of 2000, conducted by the Brazilian Institute of Geography and Statistics (IBGE) (7) ( Table-3 ). Having the frequency percentages of IPSS in several ranges of population under study, the total of risk population in each range and the criteria for indicating the type of treatment, the estimated number of individuals subjected to pharmacological and surgical treatments was obtained. The mean annual cost (September/2002) of drug treat- 
RESULTS
Population subjected to medical treatment with IPSS of 8 to 19, according to the age range is presented in Table- 4. The value obtained for medical treatment of the estimated risk population, was determined from calculation: 5,397,321 (patients) x US$ 355.00 = US$ 1,916,489,055.00.
As for surgical treatment the estimated risk population is presented in Table- Total values found for treatment of BPH in Brazil are presented in Table-6 and represent the sum of medical and surgical treatments. 
SUS -Unified Health System; AMB -Brazilian Medical Association

DISCUSSION
In 1999 it was presented a work concerning the estimated costs of BPH treatment in Brazil. At the time, the estimated population for calculation was obtained through IBGE data from 1996. We were impressed by the values determined, especially in reference to costs of medical treatment. Four years later we decided to reassess those numbers to get an idea about their evolution. There was a significant increase in risk population both for medical treatment (52.4%) and for surgical treatment (118.7%). Such data show that Brazilian population is growing older, with a significant increase in risk population for BPH treatment. Associated with the population growth is the increase in the procedure costs. Drugs cost has raised about 21.02%. SUS added about 69.19% to TURP package, noting the addition of anesthetist's medical fees, which were separated from the package. AMB table plus hospital expenses suffered an increase of 26.6% for TURP. The sum of these factors has promoted an increased in the costs of annual medical treatment for the risk population total of US$ 877,292,155.00, that is, 84.5%. On the other hand, annual SUS cost to finance surgical treatment of risk population has increased about US$ 258,360,324.00, which means an addition of 270.2%. As for TURP costs according to AMB table for medical fees plus hospital costs, it was calculated an addition of US$ 1,216,702,071.00, which represents an increase of 176.9%. This work's intention is not discuss if such increases could represent substantial gains to urologists or not, but to analyze the necessary amount to be spent by the community in order to finance BPH treatment. Obviously, these costs can present variations with time due to the annual percentage increase in risk population, which were calculated in 24.99% for both groups. For the medical group this percentage is added yearly. However for the surgical group this percentage falls over the non-operated amount.
Another interesting fact is that the total resources spent with medical treatment are really significant, showing that the urologist must be moderate in his/her indications so that he/she will not burden society too much.
All theses facts induce us to foresee that the treatment of BPH in a not-so-far future can become a public health problem for Brazilian society, since the current estimate would be of costs around 2.26 to 3.83 billion dollars, added by the yearly increase in the risk population (24.99%) for the group under medical treatment and over the non-operated amount of the surgical group.
